Deenova Expands its Italy Winning Streak with 9 Year Tender at ASST Vimercate Hospitals
12.7.2021 09:00:00 EEST | Business Wire | Press release
Deenova today publicly disclosed that its remarkable European market success in 2020 steadily expanded to Italy during 2021, with the recent Public Tender Award won by Deenova at ASST Vimercate Hospitals for multiple D1 unit-dose robots including 6 All-In-1 Stations, 40 modules of Barcode, Fridge and/or Narcotic cabinets, and the continuous utilisation of Deenova’s world-class of full service unit-dose and multi-dose medications solutions.
Giorgio Pavesi, Managing Director of Deenova in Italy stated: “It is a confirmation of our European market momentum that started in 2020, to combine new business robot and service contracts at premier hospitals in Europe with additional purchase of technologies and complex services by previous Deenova customers, clearly showing a high level of continued satisfaction with our automation solutions amongst our existing customer base, such as Vimercate Hospital.”
ASST Vimercate Hospitals are 5 state-of-the-art acute and non acute hospitals in the territory of Brianza, where architecture, technology and organisation are all aimed at placing the patient at the centre of the logistic and diagnostic-therapeutic paths. They include: Hospital of Vimercate, Hospital Presidium of Desio, Hospital of Carate Brianza, Seregno Hospital Presidium, Presidio Ospedaliera di Giussano with approximately 900 beds.
Christophe Jaffuel, Deenova Chief Commercial Officer, stated: “These 2 latest multi-year Public Tender wins (San Camillo and ASST Vimercate) highlight Deenova main differentiating characteristics compared to other suppliers: patient care crafted for compliance, better safety and therapy compliance, and 24/7 availability.”
Since 2004, Deenova is the undisputed leading supplier of combined mechatronics (robotic and automation) solutions for closed loop medications and medical devices traceability in the healthcare industry, anytime and anywhere.
Deenova’s unique and fully integrated solutions have and will greatly contribute to ease healthcare providers’ growing pressures to: simultaneously improve patient safety, reduce therapy errors, minimise waste and controlled substance diversion, contain costs, and diminish the gap between rising patient volume/acuity and scarce medical staff.
Deenova guarantees the simplification of all processes related to the management of medications and implantable/disposable medical devices with an expected cost savings range between 15% and 25%.
Please visit www.deenova.com for additional information.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210711005024/en/
Contact information
Contacts at Deenova:
Christophe Jaffuel, Martina Buccianti
+39 0523 785311
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Splio Enters a New Phase of Its Regional Development in Southern Europe19.5.2026 10:00:00 EEST | Press release
A few months after launching its AI-first CRM, Splio is entering a new phase of its development in Southern Europe. Already established for more than 12 years in Spain, Portugal and Italy, the company has chosen to invest further in the region, convinced that it combines economic potential with rapidly evolving digital usage. Antoine Parizot, Splio’s co-CEO, is relocating to Barcelona, where the company’s historic office is based. At the same time, Donald Pontabry, COO and based in Spain for more than eight years, is taking responsibility for Southern Europe in addition to his current role. This development is supported by a regional team of around thirty people, spanning partnerships, business development, customer success and support. The team already works with around one hundred local clients, including Bodeboca, QVC, GoodNews, Gocco, Equivalenza, Lola Casademunt, Casa Viva, Piazza Italia, Conforama and Gaudi. “We see Southern Europe as much more than a region where we have a long-
KfW, Germany’s largest national promotional bank, future-proofs regulatory reporting, by migrating to Regnology Reporting Hub (RRH)19.5.2026 09:33:00 EEST | Press release
Regnology, a leading provider at the intersection of regulatory, risk, and supervisory technology, today announced that KfW Bankengruppe (KfW) is advancing its long-term partnership with the company by electing to migrate to the next-generation Regulatory Reporting Hub (RRH). The solution will be delivered as a cloud-native service on Rcloud, Regnology’s high-performance cloud architecture layer. This strategic move to the modern RRH platform future-proofs the mission-critical reporting functions for one of the world's leading promotional banks. Headquartered in Frankfurt am Main, KfW is a public‑law institution dedicated to supporting sustainable economic, social and ecological development in Germany, across Europe and globally. Regnology’s foresight led to the 2023 launch of Rcloud, its state-of-the-art architecture layer built on Google Cloud, enabling next‑generation solutions like RRH to operate with the full power of cloud-native design delivering the clear operational and strate
ATB Therapeutics Appoints Mark Throsby as CEO to Lead Next Phase of Growth19.5.2026 09:00:00 EEST | Press release
ATB Therapeutics (“ATB” or the “Company”), a biopharmaceutical company advancing next-generation antibody-based therapies for oncology and immunology, today announced the appointment of Mark Throsby, PhD, as Chief Executive Officer. The leadership transition marks an important milestone as the Company continues its evolution from a startup into a development-stage biopharmaceutical company. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260513198633/en/ ATB Therapeutics Appoints Mark Throsby as CEO to Lead Next Phase of Growth Mark Throsby has served as Executive Chairman and Chief Scientific Officer since 2024, during which time he supported the Company’s growth, including the successful closing of its Series A financing, the expansion of the scientific team, and the advancement of its therapeutic programs. In his new role, he will lead ATB’s strategy and senior leadership team as the Company prepares to enter clinical deve
TREASoURcE Shows How Circular Economy Solutions Can Move Beyond Pilots Across Sectors and Regions19.5.2026 08:00:00 EEST | Press release
Across Europe, many circular economy solutions struggle to move beyond isolated pilots and into real-world deployment at scale. New approaches are needed that combine technical feasibility, market relevance and citizen engagement, while remaining adaptable to local contexts. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260518914041/en/ TREASoURcE addressed circular economy challenges across energy, plastics and biobased side streams, combining technical solutions with stakeholder and citizen engagement. The EU-funded TREASoURcE project provides evidence that systemic, citizen-engaged circular economy solutions can be developed, tested and prepared for replication across regions. Using a common regional approach, the project combined real-life demonstrations, cross-value chain collaboration and early consideration of transferability to translate circular economy concepts into practical solutions in the fields of energy, mat
Shufti Recognised as Dual Leader in Liminal's 2026 Age Verification and Age Estimation Indexes, with Exceptional Ratings Across Both Benchmarks19.5.2026 08:00:00 EEST | Press release
Shufti has been named a Leader in both the Age Verification and Age Estimation categories of Liminal’s 2026 Index Report, receiving an Exceptional rating for Market Presence across both. Liminal, an actionable intelligence firm, evaluates identity verification vendors across Product Execution, Strategy, and Market Presence, assessing scalability, accuracy, fraud resistance, innovation, and user experience. Out of 189 vendors assessed in the Age Verification Index, only 17 achieved Leader status. Shufti was among them and exceeded the leadership threshold with a 64% Product Execution score and a 92% Strategy score. In Age Estimation, Shufti again ranked among 17 Leaders from 80 evaluated vendors, exceeding leadership thresholds across core evaluation pillars, alongside an Exceptional Market Presence rating in both categories. “Achieving Leader status in both Age Estimation and Age Verification reflects that our solutions are built for accurate, scalable, and privacy-first age assurance
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom